H-SVYDFFVWL^-OH

Ref. 3D-PP49084

Informations sur le produit

• Nom: H-SVYDFFVWL^-OH

Description

Peptide H-SVYDFFVWL^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SVYDFFVWL^-OH include the following: Trp2 Peptide-Assembled Nanoparticles with Intrinsically Self-Chelating 64Cu Properties for PET Imaging Tracking and Dendritic Cell-Based Immunotherapy against Z He, H Jia, M Zheng, H Wang, W Yang - ACS Applied Bio , 2021 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsabm.1c00480 An altered peptide ligand for naaca¯ve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity Y Tang, Z Lin, B Ni, J Wei, J Han, H Wang - Cancer Immunology , 2007 - Springerhttps://link.springer.com/article/10.1007/s00262-006-0195-x Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen XY Wang , X Sun, X Chen, J Facciponte - The Journal of , 2010 - journals.aai.orghttps://journals.aai.org/jimmunol/article/184/11/6309/82273 Co-assembled and self-delivered epitope/CpG nanocomplex vaccine augments peptide immunogenicity for cancer immunotherapy X Shi, H Song, C Wang, C Zhang , P Huang - Chemical Engineering , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1385894720319823 An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity X He , S Zhou , B Quinn, D Jahagirdar , J Ortega - Cancer immunology , 2022 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/10/3/314/681732 Self-assembling Bioactive Peptides for Supramolecular Cancer Immunotherapy S Li, X Yan, J van Hest - Peptide Self-Assembly and , 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/9783527841264.ch22 Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2-restricted T cell epitopes R Hoppes, R Oostvogels , JJ Luimstra - The Journal of , 2014 - journals.aai.orghttps://journals.aai.org/jimmunol/article/193/10/4803/97379 Synthetic, Supramolecular, and Self-Adjuvanting CD8+ T-Cell Epitope Vaccine Increases the Therapeutic Antitumor Immunity P Yang, H Song, Z Feng , C Wang - Advanced , 2019 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adtp.201900010 Enhancing anti-tumor immunity through local gene delivery to lymph nodes NM Dold, CM Jewell - Journal for ImmunoTherapy of Cancer, 2015 - search.proquest.comhttps://search.proquest.com/openview/c89ccc33320ef4421046e500cde24800/1?pq-origsite=gscholar&cbl=2040222 Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model MWJ Schreurs, AAO Eggert, AJ de Boer, JLM Vissers - Cancer Research, 2000 - AACRhttps://aacrjournals.org/cancerres/article-abstract/60/24/6995/506996 In Vivo Plasmid Electroporation Induces Tumor Antigen-specific CD8+ T-Cell Responses and Delays Tumor Growth in a Syngeneic Mouse Melanoma M Kalat, Z Küpcü, S Schüller, D Zalusky - Cancer research, 2002 - AACRhttps://aacrjournals.org/cancerres/article-abstract/62/19/5489/509241 Nanostructured SL9-CpG Lipovaccines Elicit Immune Response for the Treatment of Melanoma LM Mu, L Liu, R Liu, YF Du, Q Luo, JR Xu - International Journal of , 2019 - mdpi.comhttps://www.mdpi.com/1422-0067/20/9/2207 A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model JA McWilliams, SM McGurran, SW Dow - The Journal of , 2006 - journals.aai.orghttps://journals.aai.org/jimmunol/article/177/1/155/37653 Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination J Steitz, D Tormo, D Schweichel, T Tuting - Cancer Gene Therapy, 2006 - nature.comhttps://www.nature.com/articles/7700894 Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects HI Cho, E Celis - Cancer research, 2009 - AACRhttps://aacrjournals.org/cancerres/article-abstract/69/23/9012/551125 Toward personalized peptide-based cancer nanovaccines: a facile and versatile synthetic approach H Kakwere , ES Ingham, R Allen - Bioconjugate , 2017 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.7b00502 Trp2 Peptide Vaccine Adjuvanted with (R)-DOTAP Inhibits Tumor Growth in an Advanced Melanoma Model EA Vasievich, S Ramishetti, Y Zhang - Molecular , 2012 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/mp200350n Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2 CE Myers, SO Dionne, K Shakalya, D Mahadevan - Human immunology, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0198885907004831 A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma C Capasso, A Magarkar , V Cervera-Carrascon - , 2017 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2017.1319028 Novel C5a agonist-based dendritic cell vaccine in a murine model of melanoma AA Floreani, SJ Gunselman, AJ Heires, RJ Hauke - Cell cycle, 2007 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.4161/cc.6.22.4899 Hydrophobic and electrostatic interactions between cell penetrating peptides and plasmid DNA are important for stable non-covalent complexation and intracellular A Upadhya , PC Sangave - Journal of Peptide Science, 2016 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.2927

• Marque: Biosynth